Na/K-ATPase ligand and uses thereof in wound healing

Patent metadata

Field	Value
Publication number	US-9492463-B2
Application number	US-201514792375-A
Country	US
Kind code	B2
Filing date	Jul 6, 2015
Priority date	Jan 31, 2006
Publication date	Nov 15, 2016
Grant date	Nov 15, 2016

Abstract

Methods and compositions for detecting, treating, characterizing, and diagnosing interstitial lung and/or fibrotic diseases are described.

First claim

What is claimed is:

1. A method of enhancing wound closure comprising administering by injection or topical formulation a composition comprising a pharmacologically effective amount of at least one cardiac glycoside that binds to the Na/K-ATPase in a pharmaceutically or cosmetically acceptable vehicle, the effective amount ranging from about 0.1 nM to about 10 nM, wherein the composition enhances skin fibroblast collagen production to enhance wound closure;
wherein the cardiac glycoside inhibits the Na/K-ATPase at a concentration similar to that of marinobufagenin (MBG), wherein said concentration is log units above 0.1 nM.

2. The method of claim 1 , wherein the cardiac glycoside is a cardenolide or a bufadienolide.

3. The method of claim 1 , wherein the cardiac glycoside is derived from either plants or animals, is semi-synthesized, or is synthesized.

4. The method of claim 1 , wherein the cardiac glycoside is derived from plants.

5. The method of claim 1 , wherein the composition is in a dosage form selected from the group consisting of suspension tablets, powders, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols, ointments, creams, lotions, solutions, gels, and pastes.

6. The method of claim 1 , wherein the cardiac glycoside functions as a stimulator of the Na/K-ATPase signalosome.

7. The method of claim 1 , wherein the composition induces interaction of the Na/K-ATPase with lipids, protein kinases, phosphatases, ion channels, transporters, and other soluble membrane proteins to form various Na/K-ATPase signalosome complexes.

8. A method according to claim 1 , including the step of enhancing skin fibroblast collagen production by topical or injected administration of the pharmaceutical composition.

Assignees

• Univ Toledo

Inventors

• Xie Zi-Jian
• Shapiro Joseph I

Classifications

• A61P9/06

  Antiarrhythmics · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P9/04

  Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title

• A61P9/12

  Antihypertensives · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title